Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. Today, we learn about how scientists had a happenstance discovery about tumor-suppressor genes and used them to target aggressive pediatric tumor cells. We see a U.K. health agency make a controversial call about an ALS drug made by Biogen, and more.
Read Original Article: Aardvark Therapeutics gearing up for $200 million IPO »
